302 related articles for article (PubMed ID: 20512796)
1. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
3. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
4. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A
Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710
[TBL] [Abstract][Full Text] [Related]
5. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
[TBL] [Abstract][Full Text] [Related]
6. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
7. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
9. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
[TBL] [Abstract][Full Text] [Related]
11. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Dowsett M; Nicholson RI; Pietras RJ
Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
[TBL] [Abstract][Full Text] [Related]
12. Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
Jung YS; Chun HY; Yoon MH; Park BJ
Neoplasia; 2014 Dec; 16(12):1070-81. PubMed ID: 25499220
[TBL] [Abstract][Full Text] [Related]
13. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Robertson JF
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):209-12. PubMed ID: 11850227
[TBL] [Abstract][Full Text] [Related]
14. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
16. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
17. Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer.
Grinshpun A
Curr Opin Oncol; 2023 Nov; 35(6):472-478. PubMed ID: 37427531
[TBL] [Abstract][Full Text] [Related]
18. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
19. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
20. Targeted degradation of proteins by small molecules: a novel tool for functional proteomics.
Zhang D; Baek SH; Ho A; Lee H; Jeong YS; Kim K
Comb Chem High Throughput Screen; 2004 Nov; 7(7):689-97. PubMed ID: 15578931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]